Discontinue use if hypersensitivity reactions occur; in hyperlactatemia, metabolic/lactic acidosis, progressive hepatomegaly or rapidly elevating aminotransferase levels. Patients co-infected w/ hepatitis C; chronic active hepatitis B or C; obese. Risk for lactic acidosis; mitochondrial dysfunction; lipodystrophy; immune reactivation syndrome; autoimmune disorders; osteonecrosis; opportunistic infections; HIV transmission; MI. Screen for HLA B*5701 allele carriage prior to initiation. Concomitant use w/ other medicinal products inducing skin toxicity eg, NNRTIs; ribavirin; triple nucleoside therapy eg, abacavir, lamivudine, zidovudine. Hepatitis or other known risk factors for hepatic disease; significant underlying hepatic disease; moderate to severe hepatic impairment. Avoid use in end-stage renal disease. Not recommended during pregnancy. Not to be used during lactation. Childn <3 mth. Elderly >65 yr.